Application of bulleyaconitine A in preparing medicament for treating Nav1.7 ache disease

A technology for clathrin and medicine, which is applied in the application field of clathrate as a medicine for the preparation of Nav1.7 pain symptoms, and can solve the problems of prolonging the open time, hindering the rapid inactivation of voltage-gated sodium channels, and the like.

Inactive Publication Date: 2009-07-15
YUNNAN HAOPY PHARM LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In vitro electrophysiological studies of three of the mutations showed that the mutations were concentrated in the region controlling th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Each tablet contains 0.1mg of aconitin mixed with excipients to make aconitin tablets.

Embodiment 2

[0012] Each tablet contains 0.3mg of aconitin mixed with excipients and pressed into aconitin tablets.

Embodiment 3

[0014] Each tablet contains 0.5 mg of aconitin mixed with excipients and pressed to make aconitin tablets.

[0015] The excipients added to the above-mentioned Aconitin Tablets are common additional materials that have the functions of filling, binding, disintegrating and lubricating, do not have physical and chemical reactions with drugs, have no physiological effects, are non-toxic, and have no adverse reactions.

[0016] The oral usage and dosage of the above tablets are one tablet at a time, 2 to 3 times a day.

[0017] Considerations include:

[0018] 1. The interval between two medications should not be less than 6 hours to keep the blood drug concentration within the therapeutic window.

[0019] 2. In case of adverse reactions, atropine can be injected intravenously, and the dose can be reduced or discontinued; if the reaction is severe, it should be treated as aconitum poisoning and the drug should be stopped.

[0020] 3. It is forbidden to use this product when its ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of bulleyaconitine A used for preparing medicine for treating Nav1.7 pain, which belongs to medicine containing effective organic ingredients, in particular to medicine using the bulleyaconitine A for treating a disease. The medicine contains excipient which plays roles in padding, bond, disintegration and lubrication, the bulleyaconitine A and the excipient are mixed to be pressed into tablets, and each tablet of bulleyaconitine A contains 0.1mg to 0.5mg of the bulleyaconitine A. The invention has the characteristics of rapid absorption by oral administration, low content in the brain for the medicine distributed in a body, long half life period, little toxicity, and no tolerant phenomenon or addiction.

Description

technical field [0001] The invention belongs to medicines containing effective organic ingredients, in particular to medicines for treating diseases with orthoquinone. Background technique [0002] Nav1.7 Pain includes erythematous extremity pain and paroxysmal severe pain. Primary erythematalgia (PE) is an autosomal dominant genetic disease. It usually starts in adolescence and is mostly inherited in families. Its symptoms are intermittent burning pain in the extremities, redness and swelling, and elevated temperature, usually caused by mild heat stimulation or exercise heat production. Generally, raising the limb or immersing the affected limb in cold water can relieve the symptoms, but the latter can easily lead to gangrene, and severe cases even amputation. The severe condition brings great harm to the patient's body and mind. The diseased mutant NaV1.7 was transfected into HEK293 cells, and the study found that the activation of the mutant NaV1.7 channel shifted to th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/439A61K9/20A61P29/00
Inventor 李彪
Owner YUNNAN HAOPY PHARM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap